We were delighted to welcome over forty supporters to attend our first Research Innovation Event which was held recently at the prestigious The Institute of Cancer Research in London. The event provided our supporters with an update of current projects as well as our ambitious plans to fund future projects over the next three years.
Oracle Chairman Peter Rhys Evans was joined by Professor James McCaul who spoke about the advances in Robotic Surgery and how using robots enables surgeons to access hard to reach tumours. Professor Chris Nutting spoke about how, medications following Oracle funded research, radiotherapy is now delivered to minimise the risk of complications, try which are so common with treating head and neck cancer. Side effects such as swallowing and dry mouth are two such side effects that can affect up to 90% of patients. New radiotherapy techniques, such as IMRT, which were developed by Professor Nutting have reduced symptoms significantly.
Finally, Professor Kevin Harrington spoke about the hugely promising developments in targeted therapies, virus therapies and the new MR Linac machine. All Oracle researchers attended the event where guests were able to hear individual presentations about our work.